Tela Bio Inc

NASDAQ TELA

Data sourced from

and

Download Data

Tela Bio Inc Operating Cash Flow to Sales Ratio 1 year YoY Change (%) for the year ending December 31, 2023: 28.95%

Tela Bio Inc Operating Cash Flow to Sales Ratio 1 year YoY Change (%) is 28.95% for the year ending December 31, 2023, a 509.51% change year over year. The operating cash flow to sales ratio measures the proportion of a company's operating cash flow to its total sales revenue. It is calculated by dividing the operating cash flow by the revenue. This ratio indicates the company's ability to convert its sales revenue into operating cash flow, reflecting its operational efficiency and cash generation capabilities. A higher ratio suggests a higher level of cash flow generated from sales, indicating strong profitability and effective cash management. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Tela Bio Inc Operating Cash Flow to Sales Ratio for the year ending December 31, 2022 was -98.38%, a 4.75% change year over year.
Tela Bio Inc Operating Cash Flow to Sales Ratio for the year ending December 31, 2021 was -103.29%, a 23.08% change year over year.
Tela Bio Inc Operating Cash Flow to Sales Ratio for the year ending December 31, 2020 was -134.28%, a 18.74% change year over year.
Tela Bio Inc Operating Cash Flow to Sales Ratio for the year ending December 31, 2019 was -165.24%, a 31.38% change year over year.

NASDAQ: TELA

Tela Bio Inc

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway, Malvern, PA, United States, 19355
Employees	227
Sector	Healthcare
Industry	Medical devices

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends